Guggenheim Reaffirms Buy Rating for Tempus AI (NASDAQ:TEM)

Guggenheim reiterated their buy rating on shares of Tempus AI (NASDAQ:TEM) in a report released on Tuesday,Benzinga reports.

TEM has been the subject of several other research reports. TD Cowen reiterated a “buy” rating and issued a $74.00 target price (up previously from $58.00) on shares of Tempus AI in a research note on Wednesday, February 5th. Piper Sandler reiterated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Needham & Company LLC lifted their price objective on Tempus AI from $56.00 to $70.00 and gave the stock a “buy” rating in a report on Tuesday. Stifel Nicolaus lowered Tempus AI from a “buy” rating to a “hold” rating and upped their target price for the company from $45.00 to $65.00 in a research note on Monday, November 11th. Finally, Wolfe Research assumed coverage on Tempus AI in a research report on Friday, December 13th. They issued an “outperform” rating and a $60.00 target price for the company. Five investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. Based on data from MarketBeat.com, Tempus AI presently has a consensus rating of “Moderate Buy” and a consensus price target of $60.55.

Tempus AI Stock Down 11.2 %

Shares of Tempus AI stock opened at $55.30 on Tuesday. The company has a debt-to-equity ratio of 8.17, a current ratio of 2.69 and a quick ratio of 2.55. The firm has a fifty day moving average price of $52.29 and a two-hundred day moving average price of $52.27. Tempus AI has a fifty-two week low of $22.89 and a fifty-two week high of $91.45.

Insider Buying and Selling at Tempus AI

In related news, CAO Ryan M. Bartolucci sold 13,770 shares of Tempus AI stock in a transaction dated Friday, January 31st. The shares were sold at an average price of $60.00, for a total transaction of $826,200.00. Following the completion of the transaction, the chief accounting officer now directly owns 57,237 shares of the company’s stock, valued at $3,434,220. This trade represents a 19.39 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, COO Ryan Fukushima sold 120,000 shares of the company’s stock in a transaction dated Wednesday, December 11th. The stock was sold at an average price of $42.51, for a total transaction of $5,101,200.00. Following the sale, the chief operating officer now directly owns 1,007,207 shares in the company, valued at $42,816,369.57. This represents a 10.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last three months, insiders sold 5,823,701 shares of company stock valued at $320,906,059.

Institutional Investors Weigh In On Tempus AI

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Kovitz Investment Group Partners LLC acquired a new position in Tempus AI in the third quarter worth $1,367,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Tempus AI in the fourth quarter valued at about $1,091,000. Sumitomo Mitsui Trust Group Inc. lifted its position in Tempus AI by 1,591.2% during the 3rd quarter. Sumitomo Mitsui Trust Group Inc. now owns 1,217,699 shares of the company’s stock worth $68,922,000 after buying an additional 1,145,698 shares in the last quarter. Mirae Asset Global Investments Co. Ltd. bought a new stake in Tempus AI during the 4th quarter worth about $178,000. Finally, Captrust Financial Advisors acquired a new stake in Tempus AI in the 3rd quarter valued at about $2,726,000. 24.22% of the stock is owned by institutional investors and hedge funds.

Tempus AI Company Profile

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.